These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20722614)

  • 1. A comparison between bisphosphonates and other treatments for osteoporosis.
    Le Goff B; Guillot P; Glémarec J; Berthelot JM; Maugars Y
    Curr Pharm Des; 2010; 16(27):3037-44. PubMed ID: 20722614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
    Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
    Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteoporosis].
    Buck G; Perger L; Bischoff-Ferrari HA
    Praxis (Bern 1994); 2011 Jul; 100(14):821-32. PubMed ID: 21732293
    [No Abstract]   [Full Text] [Related]  

  • 4. [The necessity of cost-effectiveness analysis in osteoporosis].
    Lamy O; Krieg MA
    Rev Med Suisse; 2007 Jun; 3(115):1521-5. PubMed ID: 17682796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis treatment in postmenopausal women with pre-existing fracture.
    Cheng MH; Chen JF; Fuh JL; Lee WL; Wang PH
    Taiwan J Obstet Gynecol; 2012 Jun; 51(2):153-66. PubMed ID: 22795089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
    Murphy DR; Smolen LJ; Klein TM; Klein RW
    BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological management of severe postmenopausal osteoporosis.
    Gaudio A; Morabito N
    Drugs Aging; 2005; 22(5):405-17. PubMed ID: 15903353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisphosphonate].
    Hagino H
    Nihon Rinsho; 2011 Jul; 69(7):1253-7. PubMed ID: 21774367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
    Lewiecki EM
    J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.
    Palacios S; Brincat M; Erel CT; Gambacciani M; Lambrinoudaki I; Moen MH; Schenck-Gustafsson K; Tremollieres F; Vujovic S; Rees M; Rozenberg S
    Maturitas; 2012 Feb; 71(2):194-8. PubMed ID: 22176952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to manage postmenopausal osteoporosis?
    Body JJ
    Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-Related Adverse Events of Osteoporosis Therapy.
    Khan M; Cheung AM; Khan AA
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):181-192. PubMed ID: 28131131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.
    Carvalho NN; Voss LA; Almeida MO; Salgado CL; Bandeira F
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2675-80. PubMed ID: 21752890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of osteoporosis: one step forward, two steps back.
    Stevenson JC
    Menopause Int; 2011 Dec; 17(4):137-41. PubMed ID: 22120943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New findings with old drugs for osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2009 Feb; 10(3):513-6. PubMed ID: 19191686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.